业界动态监管公开信息 · FDA

FDA授予tovorafenib加速批准,用于复发或难治性BRAF改变的小儿低级别胶质瘤患者

FDA Drugs · 2026-11-13 00:23

正文 · 中文译文

FDA授予托沃拉非尼加速批准,用于复发或难治性BRAF改变的小儿低级别胶质瘤患者 癌症批准 肿瘤学(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已验证临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2024年4月23日,美国食品药品监督管理局(FDA)授予托沃拉非尼(Ojemda,Day One Biopharmaceuticals, Inc.)加速批准,用于6个月及以上、携带BRAF融合或重排、或BRAF V600突变的复发或难治性小儿低级别胶质瘤(LGG)患者。 这代表FDA首次批准用于治疗携带BRAF重排(包括融合)的小儿LGG患者的全身性疗法。 Ojemda的完整处方信息将在此处发布。 疗效与安全性 在FIREFLY-1(NCT04775485)研究入组的76例患者中评估了疗效。该研究是一项多中心、开放标签、单臂试验,纳入携带当地实验室检测到的激活型BRAF改变、且既往接受过至少一线全身治疗的复发或难治性儿童低级别胶质瘤(LGG)患者。患者须有影像学进展的记录证据以及至少一个可测量病灶。携带其他激活型分子改变(如IDH1/2突变、FGFR突变)的肿瘤患者,或已知或疑似诊断为1型神经纤维瘤病的患者被排除。患者根据体表面积接受tovorafenib治疗(范围:290至476 mg/m2,最大剂量600 mg),每周一次,直至出现疾病进展或不可接受的毒性。 主要疗效结局指标为总缓解率(ORR),定义为根据儿童神经肿瘤低级别胶质瘤疗效评估(RAPNO-LGG)标准,经盲法独立中心审查(BICR)评定为完全缓解(CR)、部分缓解(PR)或轻微缓解(MR)的患者比例。其他疗效结局指标包括缓解持续时间(DoR)。ORR为51%(95% CI:40,63),中位DoR为13.8个月(95% CI:11.3,不可估计)。 最常见的不良反应(≥30%)为皮疹、毛发颜色改变、疲乏、病毒感染、呕吐、头痛、出血、发热、皮肤干燥、便秘、恶心、痤疮样皮炎和上呼吸道感染。最常见的3级或4级实验室异常(>2%)为磷酸盐降低、血红蛋白降低、肌酸磷酸激酶升高、丙氨酸氨基转移酶升高、白蛋白降低、淋巴细胞降低、白细胞降低、天冬氨酸氨基转移酶升高、钾降低和钠降低。 基于体表面积(BSA)的推荐tovorafenib剂量为380 mg/m2口服,每周一次(最大推荐剂量为600 mg口服,每周一次),可与食物同服或不同服,直至疾病进展或出现不可耐受的毒性。Tovorafenib有速释片剂或口服混悬液两种剂型。尚未确定BSA低于0.3 m2患者的推荐剂量。 加快审批程序 本审评使用了评估辅助工具(Assessment Aid),这是申请人自愿提交的材料,用以促进FDA的评估。 本申请基于总缓解率和缓解持续时间获得了加速批准。持续批准可能取决于确证性试验中临床获益的验证。 本申请获得了优先审评、突破性疗法认定和孤儿药认定。FDA的加快审批程序在《行业指南:严重疾病药物和生物制品的加快审批程序》中有所描述。 医疗保健专业人员应将所有疑似与任何药物和器械使用相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 如需针对研究性肿瘤产品的单患者IND(临床试验新药申请)协助,医疗保健专业人员可致电OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 在X(原Twitter)上关注肿瘤卓越中心 @FDAOncology。 内容更新日期: 05/22/2024 受监管产品 药物 肿瘤学

正文 · 英文原文

FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This represents the first FDA approval of a systemic therapy for the treatment of patients with pediatric LGG with BRAF rearrangements, including fusions. Full prescribing information for Ojemda will be posted here. Efficacy and Safety Efficacy was evaluated in 76 patients enrolled in FIREFLY-1 (NCT04775485), a multicenter, open-label, single-arm trial in patients with relapsed or refractory pediatric LGG harboring an activating BRAF alteration detected by a local laboratory who had received at least one line of prior systemic therapy. Patients were required to have documented evidence of radiographic progression and at least one measurable lesion. Patients with tumors harboring additional activating molecular alterations (e.g., IDH1/2 mutations, FGFR mutations) or with a known or suspected diagnosis of neurofibromatosis type 1 were excluded. Patients received tovorafenib based on body surface area (range: 290 to 476 mg/m2, up to a maximum dose of 600 mg) once weekly until they experienced disease progression or unacceptable toxicity. The major efficacy outcome measure was overall response rate (ORR), as defined as the proportion of patients with complete response (CR), partial response (PR), or minor response (MR) by blinded independent central review (BICR) based on Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma (RAPNO-LGG) criteria. Additional efficacy outcome measures included duration of response (DoR). The ORR was 51% (95% CI: 40, 63) and median DoR was 13.8 months (95% CI: 11.3, not estimable). The most common adverse reactions (≥30%) were rash, hair color changes, fatigue, viral infection, vomiting, headache, hemorrhage, pyrexia, dry skin, constipation, nausea, dermatitis acneiform, and upper respiratory tract infection. The most common Grade 3 or 4 laboratory abnormalities (>2%) were decreased phosphate, decreased hemoglobin, increased creatinine phosphokinase, increased alanine aminotransferase, decreased albumin, decreased lymphocytes, decreased leukocytes, increased aspartate aminotransferase, decreased potassium, and decreased sodium. The recommended tovorafenib dose based on body surface area (BSA) is 380 mg/m2 orally once weekly (the maximum recommended dosage is 600 mg orally once weekly) with or without food until disease progression or intolerable toxicity. Tovorafenib is available as an immediate release tablet or as an oral suspension. A recommended dosage for patients with BSA less than 0.3 m2 has not been established. Expedited Programs This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials. This application was granted priority review, breakthrough designation and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncology. Content current as of: 05/22/2024 Regulated Product(s) Drugs Oncology

English
FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界